COMPANY PROFILE

Secretome Therapeutics

Explore full profile

Developing the stem cell secretome and focus on onconephrology

Dallas, United StatesFounded 2018Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2026

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Secretome Therapeutics

Secretome Therapeutics is pioneering the development of secretome-based therapies, focusing on the anti-inflammatory and pro-mitochondrial properties of stem cell secretions. The company operates in the biopharmaceutical sector, specifically targeting onconephrology, which deals with kidney-related issues in cancer patients. Their flagship product, STM 21, aims to mitigate the inflammatory toxicities associated with cancer treatments. Secretome Therapeutics serves healthcare providers and patients undergoing cancer treatment. The business model revolves around research and development, clinical trials, and eventual commercialization of their secretome-based therapies. Revenue is generated through product sales, partnerships, and potentially licensing agreements.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Dallas, United States
Employees: 17
Open positions: 2
Dealroom signal: 48.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Secretome Therapeutics.

See all news

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	May 2026	$30M	$120M	RA Capital Management	↗
GRANTOther financing	Mar 2026	$250K	—	Parent Project Muscular Dystrophy	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Secretome Therapeutics website traffic

Latest recorded traffic for Secretome Therapeutics is 1.6K monthly website visits, up 60% over the last three months. Secretome Therapeutics's team grew 13.3% over the past year.

Latest monthly visits1.6K 3-month web change+60% 1-year team growth+13.3%

Monthly website visitsJan 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAllotera TherapeuticsDeveloping off-the-shelf cellular therapies for cancer	St. Louis, United States	Operational	47	$351M	$860M
ETEmergence TherapeuticsEuropean biopharmaceutical company developing novel ADC immuno-therapeutics to treat high-unmet need cancers	Duisburg, Germany	Acquired
ATAtsena TherapeuticsBringing the life-changing power of genetic medicine to reverse or prevent blindness	Durham, United States	Operational
ADAdaptateDeveloping therapeutic antibodies to modulate gamma delta T cell activity for innovative immunotherapy solutions	London, United Kingdom	Acquired
SPSpectropathAn imaging technology company that allows physicians to immediately recognize targeted tissues such as cancer in real time during surgery, therapeutic, or diagnostic procedures	Atlanta, United States	Closed
SBSensei BiotherapeuticsAn innovator in the field of next-generation cancer immunotherapies	Gaithersburg, United States	Operational
OLOlgramInnovations from the sea to tackle antibiotic resistance \| Olgram	Paris, France	Operational
LULucencePrecision oncology company dedicated to creating state-of-the-art, highly sensitive liquid biopsy tests for early disease detection and personalized treatment selection	Palo Alto, United States	Operational